121 related articles for article (PubMed ID: 37502847)
1. Taxane-based Chemotherapy is Effective in Metastatic Appendiceal Adenocarcinoma.
Dansby J; More A; Zeineddine M; Yousef A; Bent A; Dayyani F; Wolff R; Overman M; Shen JP
medRxiv; 2023 Jul; ():. PubMed ID: 37502847
[TBL] [Abstract][Full Text] [Related]
2. Taxane-Based Chemotherapy Is Effective in Metastatic Appendiceal Adenocarcinoma.
Dansby J; More A; Zeineddine M; Yousef A; Bent A; Dayyani F; Wolff R; Overman M; Shen JP
Oncologist; 2023 Dec; 28(12):e1303-e1305. PubMed ID: 37738316
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Systemic Chemotherapy in Patients With Low-grade Mucinous Appendiceal Adenocarcinoma: A Randomized Crossover Trial.
Shen JP; Yousef AM; Zeineddine FA; Zeineddine MA; Tidwell RS; Beaty KA; Scofield LC; Rafeeq S; Hornstein N; Lano E; Eng C; Matamoros A; Foo WC; Uppal A; Scally C; Mansfield P; Taggart M; Raghav KP; Overman MJ; Fournier K
JAMA Netw Open; 2023 Jun; 6(6):e2316161. PubMed ID: 37261831
[TBL] [Abstract][Full Text] [Related]
4. CabaGast: multicentre, Phase II study with cabazitaxel in previously treated patients with advanced or metastatic adenocarcinoma of the esophagogastric junction and stomach.
Schmalenberg H; Al-Batran SE; Pauligk C; Zander T; Reichart A; Lindig U; Kleiß M; Müller L; Bolling C; Seufferlein T; Reichardt P; Kullmann F; Eschenburg H; Schmittel A; Egger M; Block A; Goetze TO
J Cancer Res Clin Oncol; 2018 Mar; 144(3):559-569. PubMed ID: 29285668
[TBL] [Abstract][Full Text] [Related]
5. Retrospective Analysis of Taxane-Based Therapy in Small Bowel Adenocarcinoma.
Aldrich JD; Raghav KPS; Varadhachary GR; Wolff RA; Overman MJ
Oncologist; 2019 Jun; 24(6):e384-e386. PubMed ID: 30598498
[TBL] [Abstract][Full Text] [Related]
6. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.
Antonarakis ES; Lu C; Luber B; Wang H; Chen Y; Nakazawa M; Nadal R; Paller CJ; Denmeade SR; Carducci MA; Eisenberger MA; Luo J
JAMA Oncol; 2015 Aug; 1(5):582-91. PubMed ID: 26181238
[TBL] [Abstract][Full Text] [Related]
7. Post-operative chemotherapy improves the survival of patients with well differentiated widespread metastatic appendiceal non-mucinous adenocarcinomas.
Yu T; Fan H; Lv Q; Li J; Wei L; Wang M; Dong J; Cai X
Ann Palliat Med; 2021 May; 10(5):5156-5170. PubMed ID: 34044560
[TBL] [Abstract][Full Text] [Related]
8. Systemic therapy for advanced appendiceal adenocarcinoma: an analysis from the NCCN Oncology Outcomes Database for colorectal cancer.
Tejani MA; ter Veer A; Milne D; Ottesen R; Bekaii-Saab T; Benson AB; Schrag D; Shibata S; Skibber J; Weiser M; Wilkinson N; Cohen SJ
J Natl Compr Canc Netw; 2014 Aug; 12(8):1123-30. PubMed ID: 25099444
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant chemotherapy outcome with taxane-based versus non-taxane protocols in gastric cancer.
Kianersi S; Salari S; Rezvani H; Araskhan MA; Shirangi A; Fathi MR; Ghorbi MD
J Educ Health Promot; 2023; 12():205. PubMed ID: 37545995
[TBL] [Abstract][Full Text] [Related]
10. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study.
Thuss-Patience PC; Shah MA; Ohtsu A; Van Cutsem E; Ajani JA; Castro H; Mansoor W; Chung HC; Bodoky G; Shitara K; Phillips GDL; van der Horst T; Harle-Yge ML; Althaus BL; Kang YK
Lancet Oncol; 2017 May; 18(5):640-653. PubMed ID: 28343975
[TBL] [Abstract][Full Text] [Related]
11. Response rates of taxane rechallenge in metastatic breast cancer patients previously treated with adjuvant taxanes.
Kucukoztas N; Oguz A; Rahatli S; Altundag O; Altundag K
J BUON; 2016; 21(5):1076-1081. PubMed ID: 27837607
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer.
Overman MJ; Adam L; Raghav K; Wang J; Kee B; Fogelman D; Eng C; Vilar E; Shroff R; Dasari A; Wolff R; Morris J; Karunasena E; Pisanic TR; Azad N; Kopetz S
Ann Oncol; 2018 Jan; 29(1):139-144. PubMed ID: 29069279
[TBL] [Abstract][Full Text] [Related]
13. Taxane-containing regimens for metastatic breast cancer.
Ghersi D; Willson ML; Chan MM; Simes J; Donoghue E; Wilcken N
Cochrane Database Syst Rev; 2015 Jun; 2015(6):CD003366. PubMed ID: 26058962
[TBL] [Abstract][Full Text] [Related]
14. The Clinical Significance of CEA, CA19-9, and CA125 in Management of Appendiceal Adenocarcinoma.
Yousef A; Yousef M; Zeineddine M; More A; Chowdhury S; Knafl M; Edelkamp P; Ito I; Gu Y; Pattalachinti V; Naini ZA; Zeineddine F; Peterson J; Alfaro K; Foo WC; Jin J; Bhutiani N; Higbie V; Scally C; Kee B; Kopetz S; Goldstein D; Uppal A; White MG; Helmink B; Fournier K; Raghav K; Taggart M; Overman MJ; Shen JP
medRxiv; 2023 Sep; ():. PubMed ID: 37745596
[TBL] [Abstract][Full Text] [Related]
15. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life.
Palumbo R; Sottotetti F; Trifirò G; Piazza E; Ferzi A; Gambaro A; Spinapolice EG; Pozzi E; Tagliaferri B; Teragni C; Bernardo A
Drug Des Devel Ther; 2015; 9():2189-99. PubMed ID: 25931813
[TBL] [Abstract][Full Text] [Related]
16. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
17. Taxane rechallenge during metastatic disease in HER-2 negative breast cancer patients: Clinical activity, tolerance and survival results.
Réda M; Fouquier A; Desmoulins I; Mayeur D; Kaderbhai C; Ilie S; Hennequin A; Coudert B; Bertaut A; Ladoire S
Breast; 2023 Apr; 68():149-156. PubMed ID: 36773403
[TBL] [Abstract][Full Text] [Related]
18. Second-line Chemotherapy for Previously Treated Metastatic Small Bowel Adenocarcinoma: A Retrospective Analysis.
Nakazawa T; Narita Y; Kumanishi R; Ogata T; Matsubara Y; Nozawa K; Kato K; Honda K; Masuishi T; Bando H; Kadowaki S; Ando M; Hara K; Tajika M; Muro K
Anticancer Res; 2021 Oct; 41(10):5147-5155. PubMed ID: 34593466
[TBL] [Abstract][Full Text] [Related]
19. Integrated clinico-molecular profiling of appendiceal adenocarcinoma reveals a unique grade-driven entity distinct from colorectal cancer.
Raghav K; Shen JP; Jácome AA; Guerra JL; Scally CP; Taggart MW; Foo WC; Matamoros A; Shaw KR; Fournier K; Overman MJ; Eng C
Br J Cancer; 2020 Oct; 123(8):1262-1270. PubMed ID: 32733093
[TBL] [Abstract][Full Text] [Related]
20. Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes.
Oh WK; Manola J; Babcic V; Harnam N; Kantoff PW
Urology; 2006 Jun; 67(6):1235-40. PubMed ID: 16765185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
